Hepion Pharmaceuticals Inc (NASDAQ: HEPA) stock declined to $2.14 (down 5.03%) on June 11, 2021, compared to the previous day. However, the stock gained by 36.31% in a month. If the stock sustains above $1.99 levels, it could easily reach a target of $3.5 and further to $4.50.
Joins the Russell Microcap Index
Hepion will enter the Russell Microcap Index with effect from June 28, 2021. The company would automatically qualify for inclusion in the value and growth style indexes for one year.
Recognition of the progress of CRV431
CEO of Hepion, Robert Foster, said the company achieved a significant milestone by gaining entry in the Russel Index reflecting the progress it achieved in the clinical development of CRV431 to cure ‘NASH’ and other liver diseases. Investment managers use the Russel Index as a standard for their investment strategies.
Enrolls patients for Phase 2a ‘AMBITION study
Hepion is pleased to complete the enrollment for its Phase 2a ‘AMBITION’ clinical study on May 6, 2021.
The company will conduct a Phase 2a ‘AMBITION’ clinical study in all NASH patients with 225 mg CRV431.
Robert said the company experienced difficulties recruiting patients because of the COVID-19 pandemic in the past few months. Also, inclement weather conditions at its Texas-based clinical sites caused power outages, thus compounding its Phase 2a NASH study problems.
Robert further said the company overcame all these difficulties and enrolled the subjects for its AMBITION. It will administer patients for 28 days with placebo or CRV431 and monitor the subjects for additional two weeks. Hepion’s team will examine the efficacy of CRV431 by analyzing pharmacokinetics, tolerability, and safety during 14 days.
Hepion’s CMO, Todd M. Hobbs, said it is an excellent time for its team to complete the enrollment for the AMBITION study. The company could soon complete the trial and get a complete picture of the early efficacy, PK, and safety of CRV431 in people with NASH.